- Previous Close
78.40 - Open
77.40 - Bid --
- Ask --
- Day's Range
76.80 - 78.40 - 52 Week Range
63.60 - 106.00 - Volume
2,852 - Avg. Volume
7,021 - Market Cap (intraday)
942.48M - Beta (5Y Monthly) 0.88
- PE Ratio (TTM)
19.30 - EPS (TTM)
3.99 - Earnings Date Mar 20, 2025
- Forward Dividend & Yield 0.85 (1.08%)
- Ex-Dividend Date Jun 4, 2024
- 1y Target Est
93.71
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
www.vetoquinol.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: VETO.PA
View MorePerformance Overview: VETO.PA
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VETO.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VETO.PA
View MoreValuation Measures
Market Cap
927.67M
Enterprise Value
779.43M
Trailing P/E
19.65
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.73
Price/Book (mrq)
1.71
Enterprise Value/Revenue
1.45
Enterprise Value/EBITDA
7.62
Financial Highlights
Profitability and Income Statement
Profit Margin
10.89%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
539.2M
Net Income Avi to Common (ttm)
58.7M
Diluted EPS (ttm)
3.99
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--